Dr. Stevin Zorn, Ph.D.

EVP &US Site Head, Neuroscience Research and Development, Lundbeck Research USA Stevin Zorn is Executive Vice President and US site head for Neuroscience Research at Lundbeck Research USA since 2008. He is a member of Lundbeck's Global Research Leadership Team, Development Committee, R&D Management group, R&D Executive Committee and the US Management Group. His research focus is on discovering meaningful treatments to relieve suffering from both Psychiatric and Neurological diseases and is presently heading up Lundbeck's Disease Biology Unit on Neuroinflammation to discover breakthrough therapies for psycho-neurological diseases. Dr. Zorn received a BS degree in Chemistry from Lafayette College, Easton, PA, and MS and Ph.D. degrees in Neurotoxicology and Neuropharmacology, respectively, from the University of Texas Graduate School of Biomedical Sciences, Houston, TX. Subsequent postdoctoral research studies centered on basic research of brain and intracellular neuronal signaling mechanisms at the Rockefeller University, New York, NY, in Paul Greengard's, (Nobel Laureate) laboratory of Molecular and Cellular Neuroscience.  Prior to his current position, Dr. Zorn was with Pfizer Global Research and Development for nearly 20 years. He held positions including head of General Pharmacology, Alzheimer's Disease Development Team Leader, Head of Psychotherapeutics Biology, Head of Neuroscience Therapeutics, Co-Chaired the global Neuroscience Therapeutic Area Leadership Team ...
Source: PHRMA - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Analyst, 2019, Accepted Manuscript DOI: 10.1039/C9AN01631G, PaperEmerson A Fonseca, Lucas Lafet á, Renan Cunha, Hudson Miranda, João Campos, Helton Medeiros, Marco Aurelio Romano-Silva, Raigna Silva, Alexandre Barbosa, Rafael Vieira, L Malard, Ado Jorio Global prevalence of Alzheimer ’s disease (AD) points to endemic levels, especially considering the increase on average life expectancy worldwide. AD diagnosis based on early biomarkers, in addition to a better... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Analyst latest articles - Category: Chemistry Authors: Source Type: research
DISCUSSION: These results suggest that additional genetic variation in the APOE region influences AD risk beyond APOE E2/E3/E4. PMID: 31606368 [PubMed - as supplied by publisher]
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
Authors: Ramos AR, Tarraf W, Wu B, Redline S, Cai J, Daviglus ML, Gallo L, Mossavar-Rahmani Y, Perreira KM, Zee P, Zeng D, Gonzalez HM Abstract INTRODUCTION: To determine if sleep-disordered breathing (SDB), daytime sleepiness, insomnia, and sleep duration predict seven-year neurocognitive decline in US Hispanics/Latinos (N = 5247). METHODS: The exposures were baseline SDB, daytime sleepiness, insomnia, and sleep duration. The outcomes were change in episodic learning and memory (B-SEVLT-Sum and SEVLT-Recall), language (word fluency [WF]), processing speed (Digit Symbol Substitution), and a cognitive ...
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
This study takes an important first step in understanding interactions between race/ethnicity and sex/gender on cognitive trajectories by demonstrating variability in sex/gender differences across race/ethnicity. PMID: 31606366 [PubMed - as supplied by publisher]
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
The National Institute of Aging (NIA) just announced $73 million over five years to fund two new research centers.“The Alzheimer Centers for the Discovery of New Medicines are designed to diversify and reinvigorate the Alzheimer’s disease drug development pipeline,” says the NIA online. The AlzForum.org has more details, quoting researchers saying they will change […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Conditions Neurology Source Type: blogs
Journal of Medicinal ChemistryDOI: 10.1021/acs.jmedchem.9b01012
Source: Journal of Medicinal Chemistry - Category: Chemistry Authors: Source Type: research
AbstractAlzheimer ’s disease (AD) is characterized by amyloid (A)β peptide accumulation and intracellular neurofibrillary tangles. New hypotheses have suggested that AD involves neuroinflammation and oxidative stress. Gold nanoparticles (AuNP) presents anti-inflammatory and antioxidant characteristics. The present study evaluated the AuNP treatment on an AD model (okadaic acid, OA). Male Wistar rats were injected intracerebroventricularly with OA (100 μg); 24 h later they were treated with 20-nm AuNP (at a dose 2.5 mg/kg) every 48 h for 21 days. The following groups were separated (n&...
Source: Molecular Neurobiology - Category: Neurology Source Type: research
ConclusionWe suggest a one-step quantification method for amyloid PET via a deep learning model. The model is highly reliable to quantify the amyloid PET regardless of multicenter images and various radiotracers.
Source: Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Publication date: Available online 20 September 2019Source: NeuroImageAuthor(s): Laurent Chauvin, Kuldeep Kumar, Christian Wachinger, Marc Vangel, Jacques de Guise, Christian Desrosiers, William Wells, Matthew Toews, for the Alzheimer's Disease Neuroimaging InitiativeAbstractNeuroimaging studies typically adopt a common feature space for all data, which may obscure aspects of neuroanatomy only observable in subsets of a population, e.g. cortical folding patterns unique to individuals or shared by close relatives. Here, we propose to model individual variability using a distinctive keypoint signature: a set of unique, local...
Source: NeuroImage - Category: Neuroscience Source Type: research
In conclusion, a polypharmacology approach of combining established, prolongevity drug inhibitors of specific nodes may be the most effective way to target the nutrient-sensing network to improve late-life health. Deletion of p38α in Neurons Slows Neural Stem Cell Decline and Loss of Cognitive Function in Mice https://www.fightaging.org/archives/2019/10/deletion-of-p38%ce%b1-in-neurons-slows-neural-stem-cell-decline-and-loss-of-cognitive-function-in-mice/ Researchers here provide evidence for p38α to be involved in the regulation of diminished neural stem cell activity with age. It is thought...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Alzheimer's | Biology | Brain | Chemistry | Drugs & Pharmacology | Geodon | Graduation | Laboratory Medicine | Molecular Biology | Neurology | Neuroscience | Pfizer | Pharmaceuticals | Psychiatry | Study | Texas University | Ziprasidone